Zenas BioPharma (ZBIO) Stock: Buy, Sell, or Hold?
ZBIO - Zenas BioPharma, Inc. Common Stock
$26.87
-1.36 (-4.82%)
âŧ
5d:
+8.17%
30d:
-2.29%
90d:
-18.13%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When ZBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ZBIO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ZBIO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ZBIO is currently trading at $26.87, which is considered slightly low relative to its 30-day fair value range of $25.86 to $30.67.
Technical Outlook: Technically, ZBIO is in a uptrend. Immediate support is located at $24.25, while resistance sits at $29.70. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.88 (+78.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZBIO is in a uptrend. Immediate support is located at $24.25, while resistance sits at $29.70. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.88 (+78.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$25.86 -
$30.67
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.1%
Protect Your Profits
Holding ZBIO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (49/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 78.2% below Wall St target ($47.88)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$25.86 -
$30.67
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
Âą$3.00
(11.2%)
Support & Resistance Levels
Support Level
$24.25
Resistance Level
$29.71
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.77
Wall Street Target
$47.88
(+78.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 23, 2026 7:32 PM ET
Data refreshes hourly during market hours. Next update: 8:32 PM
Data refreshes hourly during market hours. Next update: 8:32 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals IâĻ |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$144 | 75 BUY |
Advanced ZBIO Option Strategies
Professional options setups generated by AI based on today's ZBIO price and gamma walls.
